DuPont Decomposition

Why does INDRAMEDCO earn its ROE?

Breaking down Return on Equity into profitability, efficiency, and leverage.

ROE = Net Margin × Asset Turnover × Equity Multiplier

24.8% = 12.4% × 1.50 × 1.34

Latest: FY2026

Profitability

Net Margin

12.4%

6.8% →12.4%

How much profit per ₹ of revenue

Efficiency

Asset Turnover

1.50x

1.87x →1.50x

Revenue per ₹ of assets

Leverage

Equity Multiplier

1.34x

1.42x →1.34x

Assets funded by equity vs debt

Trend Analysis

ROE improved by 6.8 pp over 5 years. Driven by net margin improving (6.8% → 12.4%), asset turnover declining (1.87x → 1.50x).

Historical Decomposition

Last 5 years

YearRevenuePATNet MarginAsset TOLeverageROE
FY20220Cr0Cr6.8%1.871.4218.0%
FY20230Cr0Cr8.1%1.921.4622.7%
FY20240Cr0Cr10.3%1.661.5125.9%
FY20250Cr0Cr11.9%1.591.4327.0%
FY20260Cr0Cr12.4%1.501.3424.8%

How to read DuPont

  • Rising ROE from margin = pricing power, operational improvement (good)
  • Rising ROE from turnover = better asset utilization (good)
  • Rising ROE from leverage = more debt, amplified risk (caution)
  • Falling ROE across all three = structural deterioration (red flag)

See DCF fair value for INDRAMEDCO

Combine financial quality with intrinsic value.

See Fair Value →

DuPont decomposition from audited annual financials. Factual analysis, not investment advice.

INDRAMEDCO DuPont Analysis — ROE 24.8% | YieldIQ